0001078782-17-000598.txt : 20170505 0001078782-17-000598.hdr.sgml : 20170505 20170505163728 ACCESSION NUMBER: 0001078782-17-000598 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170426 ITEM INFORMATION: Other Events FILED AS OF DATE: 20170505 DATE AS OF CHANGE: 20170505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PixarBio Corp CENTRAL INDEX KEY: 0001623077 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEMBERSHIP SPORTS & RECREATION CLUBS [7997] IRS NUMBER: 471945113 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-204070 FILM NUMBER: 17818903 BUSINESS ADDRESS: STREET 1: 200 BOSTON AVENUE, SUITE 1875 CITY: MEDFORD STATE: MA ZIP: 02155 BUSINESS PHONE: (617) 803-8838 MAIL ADDRESS: STREET 1: 200 BOSTON AVENUE, SUITE 1875 CITY: MEDFORD STATE: MA ZIP: 02155 FORMER COMPANY: FORMER CONFORMED NAME: BMP Holdings Inc. DATE OF NAME CHANGE: 20141022 8-K 1 f8k050517_8k.htm FORM 8-K CURRENT REPORT Form 8-K Current Report


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): April 26, 2017



 

PixarBio Corporation

(Name of Small Business Issuer in its Charter)

 


Delaware

47-1945113

 (State or Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)


200 Boston Avenue, Suite 1875

Medford, MA 02155

(Address of principal executive offices)


(617) 803-8838

(Telephone Number of Principal Executive Offices)

 




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

      . Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

      . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

      . Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

      . Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))








1



ITEM 8.01 Other Events.


The consulting agreements with the following individuals were terminated by the Company, as of April 26, 2017, and they are no longer on the Clinical Advisory Board of PixarBio Corporation (the “Company”):


John Frederick Camp, MD

Mark William Pagnano, MD

Scott M. Sporer, MD

Bryan Donald Springer, MD



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 PixarBio Corporation

 

                (the Company)

 

 

 

Date: May 5, 2017

By:  

/s/ Francis M. Reynolds

 

Name: Francis M. Reynolds

Title: Chief Executive Officer




2